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ProtozoaofthegenusLeishmaniaarecausativeagentsofleishmaniasis,animportanthealthprobleminbothhumanandveterinary
medicine. Here, we describe a new heat shock protein (HSP) in Leishmania, belonging to the small HSP (sHSP) family in
kinetoplastids. The protein is highly conserved in diﬀerent Leishmania species, showing instead signiﬁcant divergence with sHSP’s
from other organisms. The humoral response elicited against this protein during Leishmania infection has been investigated in
natural infected humans and dogs, and in experimentally infected hamsters. Leishmania HSP20 is a prominent antigen for canine
hosts; on the contrary, the protein seems to be a poor antigen for human immune system. Time-course analysis of appearance of
anti-HSP20 antibodies in golden hamsters indicated that these antibodies are produced at late stages of the infection, when clinical
symptoms of disease are patent. Finally, the protective eﬃcacy of HSP20 was assessed in mice using a DNA vaccine approach prior
to challenge with Leishmania amazonensis.
Copyright © 2008 Ana M. Montalvo-´ Alvarez et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Leishmania spp., kinetoplastid protozoan parasites, cause a
diverse collection of human diseases (known as leishma-
niasis) ranging in severity from a spontaneously healing
skin ulcer to overwhelming visceral disease. Leishmaniasis
currently aﬀects an estimated 12 million people in 88
countries, with approximately 500000 new cases of visceral
leishmaniasis (VL) per year and 1.5 million for cutaneous
leishmaniasis [1]. The clinical manifestations of leishmani-
asis depend on complex interactions between the virulence
characteristics of the infecting Leishmania species and the
host immune response [2, 3] .T h u s ,C Li sc a u s e dm a i n l yb y
Leishmania major and Leishmania mexicana, whereas VL is
essentially caused by Leishmania donovani and Leishmania
infantum (also called Leishmania chagasi in Latin America).
H o w e v e r ,as i n gl eLeishmania species can produce more than
one clinical outcome; for example, Leishmania amazonensis
is known to be associated with cutaneous, diﬀuse cutaneous,
and visceral leishmaniasis in South and Central America.
Therearenovaccinesavailableatpresenttocontrolanyform
of leishmaniasis, despite considerable laboratory eﬀorts [4].
Current chemotherapy is far from satisfactory [5] and new
reagents to improve diagnosis would be desirable.
Leishmania is transmitted by the bite of infected sand-
ﬂies, where the parasite lives as extracellular promastigote
in the insect gut, to mammalian hosts. The promastigotes
invade macrophages, where they diﬀerentiate and replicate
as obligatory intracellular amastigotes. During transmission,
the parasite is subjected to a drastic change of environmental
temperature from the ambient temperature in the insect
vector to higher temperatures in the mammalian host. The
heat shock response, mediated by the induction of the heat
shock proteins (HSPs), is a homeostatic mechanism that2 Journal of Biomedicine and Biotechnology
protects cells from the deleterious eﬀects of thermal and
other environmental stresses [6]. Given these circumstances,
HSPs,inLeishmania,arebelievedtoplayessentialrolesinthe
host-pathogen interaction. Remarkably, many immunogenic
Leishmania antigens are members of diﬀerent HSP families
[7]. Thus, HSP60 [8], HSP70 [9–13], Grp78 [14], HSP83/90
[11, 12, 15], and Grp94 [16] have been described as promi-
nentantigensrecognizedbyserafromleishmaniasispatients.
The preponderance of HSPs as molecules recognized by
humanimmune systemwasillustratedin arecentstudy [17]:
from 242 protein-producing clones, which were identiﬁed
by immunoscreening with sera from VL patients, 118 (49%)
contained sequences coding for members of the HSP70 and
HSP83/90 families. However, among the main groups of
HSPs, there exists a notable absence, that is there is not any
report describing members of the small heat shock protein
(sHSP) family as antigens during Leishmania infections.
Indeed, no descriptions of such genes have been published
so far.
The sHSP family comprises the most widespread but also
the most poorly conserved group of HSPs. sHSPs have been
found in bacteria, archaea and eukaryotes [18]. Although
proteinsbelongingtothesHSPfamilyarediverseinsequence
and size, they share characteristic features: (i) a conserved α-
crystallin domain of approximately 90 residues; (ii) a small
molecular mass of 12–43kDa; (iii) tendency to form large
oligomers; (iv) increased synthesis by stress conditions; (v)
chaperone activity in suppressing protein aggregation [19].
The main aim of this work was to characterize possible
sHSPs existing in Leishmania. For this purpose, we took
advantage of the recently completed sequence of the L.
major genome [20]. In this database, we found sequence
information that helped us to identify the L. amazonensis
HSP20, which represents in turn the ﬁrst description of a
member of the sHSP family in kinetoplastids. Furthermore,
the HSP20 gene was expressed in bacteria and the puriﬁed
recombinant protein was found to be antigenic during Leish-
mania infection. Finally, the immunoprotective properties of
this protein, administered as a DNA vaccine, were analyzed
in the murine model of L. amazonensis infection.
2. MATERIALS AND METHODS
2.1. Parasites
Two L. amazonensis strains were used in this work: strain
IFLA/BR/67/pH-8 for gene cloning and strain MHOM/77/
LTB0016 for infection of mice. The virulence of the parasite
was maintained by regular passage through BALB/c mice.
Parasites were cultured at 25◦C in Schneider’s medium sup-
plemented with 10% fetal bovine serum (FBS). L. infantum
promastigotes (M/CAN/ES/96/BCN150) were cultured at
26◦C in RPMI 1640 medium supplemented with 10% FBS.
2.2. Cloningandpuriﬁcationof
therecombinantHSP20
The full-length open reading frame of L. amazonensis
HSP20 gene was PCR ampliﬁed from genomic DNA (strain
IFLA/BR/67/pH-8) with speciﬁc primers: HSP20d, 5 -CC-
AAGCTTATGTGGAGCCCGAGCAACAA-3 ; HSP20r, 5 -
CGGGATCCTTAGTCGATGGTGACTGAGT-3  (underlined
are restriction sites included in the primers for cloning
purposes). The PCR product was cloned into pCR2.1 vector
(Invitrogen Corp., San Diego, Calif., USA) to generate
pCRHSP20La clone. The HSP20 gene in pCRHSP20La
was removed by HindIII plus NotI double digestion and
cloned in the corresponding restriction sites of the pET-28b
prokaryotic expression plasmid (Novagen, Madison, Wis,
USA) to generate pETHSP20La clone. This clone was used to
express the L. amazonensis HSP20 in Escherichia coli (BL21
strain). The recombinant protein (rHSP20), which contains
an N-terminal His-tag, was puriﬁed on a Ni-NTA agarose
column,followingthemethodologyprovidedbythesupplier
(Qiagen, Hilden, Germany). The tag was not removed after
puriﬁcation.
The L. amazonensis HSP20 coding sequence contained
in the pCRHSP20La clone (see above) was obtained by
HindIII-BamHI double digestion and subcloned in the
corresponding sites of the eukaryotic expression plasmid
pcDNA3 (Invitrogen) to produce clone pcDNA3-LaHSP20.
The authenticity of the diﬀerent clones and the ﬁdelity of
the PCR-ampliﬁed fragments were veriﬁed by nucleotide
sequencing (Parque Cient´ ıﬁco de Madrid, UAM, Madrid).
The nucleotide sequence data for L. amazonensis HSP20
codingsequencehavebeendepositedattheEMBL,GenBank,
and DDBJ Nucleotide Sequence Databases under the acces-
sion no. AM712297.
2.3. Phylogeneticanalysis
The genome databases for diﬀerent Leishmania species (http:
//www.genedb.org) were used to determine sequence homo-
logues to members of the sHSP family. Protein sequences
were scanned for the occurrence of patterns stored in
PROSITE-SWISS-PROT database (http://www.expasy.org).
For phylogenetic analysis, 39 sHSP sequences were used,
choosing representative members for the main groups of
organisms: archaea, bacteria, fungi, plant, animal, and
kinetoplastids. According to previous studies [18], bacterial
sHSPs can be grouped within class A or class B, and
representative sequences for both groups have been included
in our analysis. The alpha-crystallin domain from the sHSP
sequences were aligned using the ClustalW algorithm and
the data set was used to build a phylogenetic tree with
the MEGA3 software [21]. The trees were made using the
neighbor-joining and the minimum evolution algorithms,
with Poisson-corrected amino acid distances. The reliability
of clustering patterns in the tree was tested by bootstrapping
(1000 replicates).
2.4. Seraandenzyme-linkedimmunosorbent
assays(ELISA)
Seraofgoldenhamsters(Mesocricetusauratus)wereobtained
from animals experimentally infected with L. infantum
(strain M/CAN/ES/96/BCN150). Blood samples were col-
lected monthly. Further details of these sera have beenAna M. Montalvo-´ Alvarez et al. 3
published elsewhere [22]. Human sera were obtained from
patients with VL living in Spain. All patients had clini-
cal signs of leishmaniasis and the sera were positive for
Leishmania by indirect immunoﬂuorescent tests. The pres-
ence of parasites was further demonstrated in smears of
bone marrow aspirates. Also, canine sera from naturally
Leishmania-infected dogs from the Comunidad de Madrid
(Spain) were assayed. For all animals, Leishmania infection
was determined by serological and parasitological methods.
Total Leishmania antigen was prepared from L. infantum
promastigotes by incubation of parasites in lysis buﬀer (1%
TritonX-100;150mMNaCl;10mMTris-HCl,pH8.0;1mM
PMSF) for 15 minutes. Afterwards, the suspension, kept on
ice, was sonicated until a decrease in viscosity was observed.
The insoluble material was pelleted at 10000g for 5 minutes
and the supernatant stored at −70◦C until use. ELISA assays
were carried out using standard conditions. Microplate wells
(Nunc A/S, Roskilde, Denmark) were coated with either
0.5μg/ml of puriﬁed rHSP20 (see above) or 2μg/ml of
total Leishmania antigen. Primary antibodies were assayed
at 1:200 dilution. Secondary antibodies (horseradish per-
oxidase immunoconjugates; Nordic Immunological Labora-
tories, Tilburg, The Netherlands) against human, hamster,
or dog total IgGs (H+L chains) were used at 1:1500
dilution. Finally, ortho-phenylenediamine (Dako, Glostrup,
Denmark) was used in the developing solution and the
reaction product was read at 450nm.
For each particular assay, cut-oﬀ values (Cov) were
established from the reactivity values of control-negative
sera, calculating the 99% conﬁdence interval for the mean of
a normal population. Thus, the Cov values were calculated
with the following formula: Cov=μ+2.576σ (N)−1/2,w h e r e
μ is the mean value, σ is the standard deviation, and N is the
number of control sera. At least, ten control sera were used
for each assay.
2.5. ProductionofmouseantiseraagainstrHSP20
Female 6-8-week-old BALB/c mice (Harlan Interfauna Ib´ er-
ica, Barcelona, Spain) were intradermically injected with a
mixture of 20μgo fr H S P 2 0a n d5 0 μgo fo l i g o n u c l e o t i d e
ODN-1826 (5 -TCCATGACGTTCCTGACGTT-3 ), emulsi-
ﬁed 1:1 with incomplete Freund’s adjuvant (Gibco-BRL,
Grand Island, NY, USA). Oligonucleotides containing CpG
sequences,suchasthatODN-1826,haveimmunostimulating
properties for the mouse immune system, and they are being
used in vaccination assays for inducing stronger humoral
and cellular responses against coadministered antigens [23].
Injections were repeated (using only rHSP20 emulsiﬁed
1:1 with IFA) at 2-week intervals for a total of three
immunizations. Antibody IgG-titres, evaluated by ELISA
against rHSP20, were higher than 200000.
2.6. ExpressionofLeishmaniaHSP20in
pcDNA3-LaHSP20-transfectedcells
COS7 cells were harvested from cultures in the late-loga-
rithmic phase of growth (85% conﬂuence); cells were sepa-
rated from plates by a short treatment (1-2 minutes at 37◦C)
with0.002%EDTAand0.25%trypsin.Afterwards,cellswere
washed with DMEM (supplemented with 10% FBS) and
resuspendedinthesamemediumcontaining10mMHEPES.
Two hundredμl of the cell suspension (3×106 cells) were
transferred into a 0.4-cm cuvette. After adding 5μg of plas-
mid DNA, 100μg of salmon sperm DNA and 5μlo f1 . 5m M
NaCl, cells were electroporated using a capacitance of 960μF
and a voltage of 200V. Immediately, cells were transferred
to a 100-mm culture dish containing 10ml of DMEM
(with 10% FBS) and incubated for 72 hours at 37◦Cw i t h
atmosphere of 5% CO2. Afterwards, cells were harvested,
washed two times with ice-cold PBS and immediately lysed
by addition of Laemmli’s load buﬀer. Lysates were resolved
by SDS-PAGE and transferred to nitrocellulose membranes
(Amersham, Little Chalfont, United Kingdom). The blots
were probed with the mouse anti-HSP20 antibody diluted
at 1:500 (see above). As secondary antibody, an antimouse
IgGs (horseradish peroxidase immunoconjugate) was used
at 1:2000 dilution. The blot was developed using the ECL
system (Amersham, Little Chalfont, United Kingdom).
2.7. Vaccinationandinfectionofmice
Endotoxin-free plasmid DNA, prepared using the EndoFree
Plasmid Giga Kit (Qiagen, Hilden, Germany), was used for
immunizations.BALB/cmicewereobtainedfromtheCentro
Nacional para la Producci´ on de Animales de Laboratorio
(CENPALAB, La Habana, Cuba). Mice were 6–8 weeks of
age when DNA immunizations were initiated. Groups of 6
mice were injected twice at 2-week interval intramuscularly
intheleftquadricepswith100μg of pcDNA3-LaHSP20 DNA
plasmid. As negative controls, groups of mice were injected
with either PBS or empty vector (pcDNA3, Invitrogen). Two
weeks after the last injection, the mice were challenged with
105 stationary-phase L. amazonensis promastigotes that were
suspended in 50μl of PBS and injected into the left hind
footpad. The development of lesions was monitored weekly
using a digital calliper. The contralateral footpad of each
animal represented the control value, and the swelling was
calculatedasfollows:thicknessoftheleftfootpad—thickness
of the right footpad.
3. RESULTS
3.1. IdentiﬁcationofLeishmaniasHSPs
andsequenceanalysis
WebeganthisstudybyperformingaBLASTPsearchoftheL.
major, L. infantum,a n dL. braziliensis databases (http://www
.genedb.org) using as query sequence the Saccharomyces
cerevisiae HSP26 sequence (UniProtKB/Swiss-Prot entry
P15992). Interestingly, for each Leishmania species a single
entry was retrieved: LmjF29.2450(L. major), LinJ29 V3.2560
(L. infantum), and LbrM29 V2.2420(L. braziliensis). The
BLAST scores were signiﬁcant (114 or higher), suggesting
that they may represent sHSP members in these Leishmania
species. In fact, these entries in the diﬀerent Leishmania
databases are annotated as putative HSP20 proteins. Based
on these sequences, we designed PCR primers to amplify the4 Journal of Biomedicine and Biotechnology
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Figure 1: Amino acid sequence alignment of HSP20 from Leishmania spp. and S. cerevisiae HSP26. Protein sequences of L. amazonensis
(LaHSP20, this work; EMBL accession number AM712297), L. infantum (LiHSP20, GeneDB identiﬁer LinJ29 v3.2560), L. major
(LmjHSP20, GeneDB identiﬁer LmjF29.2450), L. braziliensis (LbHSP20, GeneDB identiﬁer LbrM29 V2.2420)s H S P s ,a n dS. cerevisiae
HSP26 (UniProtKB/Swiss-Prot entry P15992) were aligned using the default settings of ClustalW (DNAstar program). Amino acid residues
conservedinallsequencesareshaded;thoseconservedinmorethan50%ofthesequencesareboxed.Thepositionofthe α-crystallindomain
isindicatedbyahorizontalline.ThedomainsweredeﬁnedusingthePrositeutilityattheExPASyProteomicsServer(http://www.expasy.org);
high scores with the HSP20/α-crystallin family proﬁle (accession number PS01031) were obtained.
HSP20 gene homologue for L. amazonensis. Figure 1 shows
the alignment of the various Leishmania HSP20s and the S.
cerevisiae HSP26. Leishmania HSP20s share a high sequence
identity (higher than 80%); instead, Leishmania HSP20s
and yeast HSP26 show ≈30% sequence identity. However,
all proteins present the signature motif of sHSPs, that is
the HSP20/α-crystallin domain (Figure 1). In addition, we
performed a phylogenetic analysis using representative sHSP
sequences from the diﬀerent groups of organisms (Figure 2).
This analysis showed a sHSP grouping consistent with
previous reports [18]. However, it should be kept in mind
that phylogenetic analyses based on sHSP sequences are
not adequate to establish evolutionary relationships between
distant groups of organisms. Thus, the valid conclusion
of our analysis was that Leishmania HSP20s are close to
each other and distant from all other sequences. Although
with a low bootstrap value, our data showed that Leish-
mania HSP20s, together Trypanosoma brucei HSP20, form
a monophyletic group, separated from the other groups of
organisms. This agrees with the belief that kinetoplastids
evolved early in evolution from the rest of eukaryotes
[24]. Furthermore, even though the bootstrap values are
very low, our analyses showed that kinetoplastid sHSPs are
closer to homologues from plants than to the corresponding
proteins from animals. Remarkably, some plant-like traits in
kinetoplastids have been reported in previous studies [25].
3.2. RecognitionofLeishmaniaHSP20byserafrom
infectedanimalsandleishmaniasispatients
As shown in Figure 1, the HSP20 sequence is well conserved
among the diﬀerent Leishmania species. For instance, L.
amazonensis and L. infantum HSP20s share 147 out of the
155 amino acids (95% of identity), and 4 out of the 8 amino
acidchangesareconservative(97.4%ofsimilarity).Withthis
remarkable degree of sequence conservation, it is expected
that both proteins are essentially cross-reactive. Indeed, as
shown below, the L. amazonensis HSP20 was recognized
by all sera from L. infantum infected dogs. Thus, the L.
amazonensis HSP20, expressed in E. coli as a His-tagged
recombinant protein (rHSP20), was used in ELISA assays to
determine whether antibodies against HSP20 are elicited inAna M. Montalvo-´ Alvarez et al. 5
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Figure 2: Phylogenetic analysis of sHSPs. Phylogenetic trees were constructed on the basis of α-crystallin/HSP20 domains by Neighbor
Joining (a) and Minimum Evolution (b) using the MEGA 3 program as described in the Material and Methods section. Sequences
(UniProtKB/TrEMBL entry): Afu, Archaeoglobus fulgidus (O28308);A j a ,Artibeus jamaicensis (P02482);A o r ,Aspergillus oryzae (Q2TXY8);
Asf, Aspergillus fumigatus (Q4WV00);A t h ,Arabidopsis thaliana (O81822);A v i ,Azotobacter vinelandii (P96193);B a p ,Buchnera aphidicola
(P57640);B j a B ,Bradyrhizobium japonicum (HspB; P70918); BjaF, Bradyrhizobium japonicum (HspF; O69243); Cel, Caenorhabditis
elegans (Q7JP52); Cim, Coccidioides immitis (Q1E6R4);C m a ,Caldivirga maquilingensis (A8MB44); Cpa, Carica papaya (Q69BI7); Ddi,
Dictyostelium discoideum (Q54I91);E c o A ,Escherichia coli (ibpA; P0C054); EcoB, Escherichia coli (ibpB; P0C058); Hsa, Homo sapiens
(P02489);L a m ,L. amazonensis;L b r ,L. braziliensis; Lin, L. infantum;L m a ,L. major; Lpi, Lygodactylus picturatus (Q6EWI0);M b a ,
Methanosarcina barkeri (Q46E59);M m u ,Macaca mulatta (P02488);M t u ,Mycobacterium tuberculosis (P0A5B7);N ﬁ ,Neosartorya ﬁscheri
(A1DEG0);O y p ,Onion yellows phytoplasma (P81958);P a b ,Pyrococcus abyssi (Q9V1L0); Pfa, Plasmodium falciparum (Q8IB02); Pis,
Pyrobaculum islandicum (A1RRY3);P g l ,Picea glauca (Q40852);S a l ,Streptomyces albus (Q53595);S c e ,S. cerevisiae (P15992);S l y ,Solanum
lycopersicum (O82545);S t h ,Streptococcus thermophilus (P80485);T b r ,Trypanosoma brucei (Q57V53);T g o ,Toxoplasma gondii (Q6DUA8);
Tsc, Trachemys scripta (Q91517);Z m a ,Zea mays (P24632). The scale represents mutational changes per residue.
experimentally infected hamsters. Remarkably, 62% of the
Leishmania infected animals developed signiﬁcant humoral
responses against the HSP20 (Figure 3). No correlation was
observed between total antigen and HSP20 reactivity values
for individual sera. Furthermore, we analyzed the time
course of appearance of anti-HSP20 antibodies along the
infection process. As illustrated in Figures 3(b) and 3(c), the
anti-HSP20 reactivity was detected long time later than the
antibodies against total Leishmania proteins.
In order to know whether the Leishmania HSP20 is
also immunogenic during natural Leishmania infections,
the reactivity against rHSP20 of a collection of sera from
canids with VL and leishmaniasis patients was determined
by ELISA (Figure 4). Interestingly, all sera from dogs with
VL reacted with rHSP20, showing reactivity values similar to
thoseobservedusingtotalLeishmaniaproteins (Figure 4(a)).
In contrast, few sera from leishmaniasis patients showed
a positive reactivity against rHSP20, suggesting that this
protein is poorly antigenic for human immune system
(Figure 4(b)).
3.3. ImmunoprotectivepotentialofLeishmania
HSP20asaDNAvaccine
The potential of parasite HSP20 to induce an immunopro-
tective response was assessed in DNA vaccination experi-
ments using the infection model of L. amazonensis in mice.
For that purpose, the L. amazonensis HSP20 gene was cloned
into the eukaryotic expression vector pcDNA3 and its appro-
priate expression was assessed in COS7 cells transfected with6 Journal of Biomedicine and Biotechnology
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Figure 3: Antigenicity of Leishmania HSP20 in experimentally infected hamsters. (a) Reactivity against total L. infantum proteins (LAg) or
L. amazonensis recombinant HSP20 (rHSP20) of sera from L. infantum infected hamsters is indicated as the mean optical density read at
450nm (OD450). Horizontal lines represent the cut-oﬀ values for the assay, which were 0.286 for LAg and 0.067 for rHSP20. (b) and (c) Time
course of the humoral response against total antigens (LAg) or rHSP20 elicited in two experimentally infected hamsters.
the construct (Figure 5(a)). Groups of BALB/c mice were
immunized with either pcDNA3-LaHSP20 DNA, empty
plasmid DNA or PBS (see materials and methods for further
details). A very low, but detectable, reactivity against rHSP20
protein was observed in the sera of LaHSP20-DNA vacci-
nated mice (data not shown). After challenge,L. amazonensis
infection was evaluated by measuring lesion development in
theinfectedfootpads(Figure 5).Lesionsprogressedsimilarly
in the three groups with no statistical diﬀerences. Thus, it
was concluded that no signiﬁcant protection or reduction in
lesion development was induced in the animals immunized
with the HSP20 DNA vaccine in the experimental conditions
used in this assay.
4. DISCUSSION
HSPs represent dominant antigens in many infections and
autoimmune diseases, inducing strong humoral and cellular
immune responses. Among the main HSP families, HSP60,
HSP70, and HSP90 have been described as major antigens
in a large number of infectious diseases caused by nema-
todes, protozoa, fungi, or bacteria. Furthermore, in variousAna M. Montalvo-´ Alvarez et al. 7
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Figure 4: Antigenicity of Leishmania HSP20 in VL human patients
and dogs. (a) Reactivity of 16 serum samples from VL dogs against
total L. infantum proteins (LAg) or L. amazonensis recombinant
HSP20 (rHSP20). (b) Reactivity of 12 sera from patients with VL
againstLAgorrHSP20.Horizontallinesrepresentsthecut-oﬀvalue
of negative sera for the LAg antigen (0.122 for canine sera and
0.232 for human sera). All sera were tested in duplicate at a 1:200
dilution.
infectious disease models, vaccination strategies using HSPs
have induced signiﬁcant protection [26]. In addition, the
unique and potent immunostimulatory properties of some
HSPs have been applied to the development of new vaccines
in which HSPs act as immunomodulatory/carrier agents
[27]. However, there are few reports describing members
of the sHSP family as antigens during infectious diseases
[28, 29]. Unlike large HSPs, the sHSPs are highly divergent in
bothsizeandprimarysequence;thisfeaturehasimpairedthe
characterizationofthecodinggenesand,inconsequence,the
analysis of the possible antigenicity of this class of proteins.
In Leishmania, several families of HSPs have been
described as prominent antigens [7, 17], but no descrip-
tion of sHSPs as antigens exists. Thus, as ﬁrst step, we
analyzed whether sHSPs are encoded in the genome of
Leishmania. For this purpose, we took advantage of the
recent completion of the genome sequences for L. major
[20], L. infantum,a n dL. braziliensis [30]. A bioinformatics
analysis of the L. major database allowed us to identify
a protein entry (LmjF29.2450) containing the α-crystallin
motif, which characterizes sHSPs. The predicted protein
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Figure 5: Analysis of protective eﬀect of DNA vaccination with
L. amazonensis HSP20 gene. (a) Expression of Leishmania HSP20
in pcDNA3-LaHSP20 transfected COS7 cells. COS7 cells were
transientlytransfectedbyelectroporationwitheitherpcDNA3DNA
(lane 1) or pcDNA3-LaHSP20 DNA (lane 2). Protein extracts were
analyzed by 12% SDS-PAGE and stained with Coomassie blue
(left panel). The expression of Leishmania HSP20 was assayed by
Western blotting using a mouse anti-HSP20 polyclonal antibody
(right panel). (b) BALB/c mice (six per group) were immunized
twice at 2-week interval with PBS, empty vector or pcDNA3-
LaHSP20. After challenge with L. amazonensis, lesion development
(footpad swelling) was monitored weekly. Each point represents the
average and standard deviations for the group.
(named HSP20) has 155 amino acids, accounting for a
molecular mass of 17.5kDa. This seems to be the sole
sHSP family member in Leishmania, since no new protein
entries were recovered from the L. major database when the
LmjF29.2450sequencewasusedasqueryinfurtherbioinfor-
matics studies. Homologous sequences were identiﬁed in the
sequence databases for L. infantum (LinJ29 V3.2560) and L.
braziliensis(LbrM29 V2.2420).Basedonthesesequences,we
designedoligonucleotidesthatallowedustoPCRamplifythe
corresponding gene in L. amazonensis. Sequence alignments
(Figure 1) and phylogenetic studies (Figure 2) revealed that
HSP20 is well conserved among Leishmania species but it8 Journal of Biomedicine and Biotechnology
is highly divergent when compared with sHSPs from other
groups of organisms.
InordertoanalyzetheantigenicpropertiesofLeishmania
HSP20, the L. amazonensis protein was expressed in E. coli
and used to determine the presence of speciﬁc IgG in the
sera of Leishmania-infected animals and human patients
with VL. Remarkably, the protein was recognized by 100%
of the sera from dogs with VL, suggesting that this protein
would be useful for serodiagnosis of canine leishmaniasis.
However, the protein has a limited antigenicity for the
human immune system, since only about 30% of the assayed
sera showed a positive reactivity. Also, we assayed the recog-
nition of the Leishmania HSP20 by sera from experimentally
infected hamsters. In this infection model, the protein was
recognized by sera from about 62% of infected animals.
In experimentally infected hamsters, analysis of the time-
course appearance of anti-Leishmania humoral response
indicated that anti-HSP20 antibodies seem to be produced
late during infection (Figure 3), coinciding with the onset
of disease symptoms. These ﬁndings would indicate that
HSP20 behaves as a pathoantigen [31], and consequently,
anti-HSP20 antibodies could be involved in the pathological
processes leading to disease progression. In addition, these
ﬁndings would point to a usefulness of this protein for
serodiagnosis of active leishmaniasis disease.
Finally, we examined whether Leishmania HSP20 could
elicitprotectiveimmunity.Recently,ithasbeenreportedthat
vaccination with Toxoplasma gondii HSP30 gene, a member
ofthesHSPfamily,inducedprotectioninmiceagainstachal-
lenge with the parasite [32]. We chose to use a DNA-based
vaccination because this approach has been demonstrated
to be adequate for inducing protection against diseases
that require cell-mediated immunity such as intracellular
protozoan parasites [33]. DNA vaccination has proven to
be a successful approach for development immunoprotective
responses in diﬀerent Leishmania-infection models, partic-
ularly for protection against L. major [4]. However, our
results indicate that immunization of susceptible BALB/c
mice with the DNA encoding Leishmania HSP20 provided
negligible protection against L. amazonensis infection. Thus,
it appears that HSP20 does not represent a feasible vaccine
candidate against L. amazonensis infection. Nevertheless,
this ﬁnding does not exclude that HSP20 would be able to
elicit an immunoprotective response against infection with
other Leishmania species as occurs for other antigens [34].
In particular, given the strong humoral response elicited
by HSP20 in naturally infected dogs, it would be of high-
value testing in dogs the immunoprotective potential of this
antigen against development of visceral leishmaniasis. On
the other hand, the results showed here do not discard a
possible use of the Leishmania HSP20 within a multivalent
vaccine.Forexample,avaccinecombination,includingDNA
encoding P4 and HSP70, induced a signiﬁcant protection
in mice against L. amazonensis,b u tn op r o t e c t i o nw a s
observed after administration of these genes separately [35].
Recently, it has been published that the L. major HSP70
is not protective in murine models of cutaneous leish-
maniasis using a prime-boost strategy [36]. Overall, these
ﬁndings could be indicating that Leishmania HSPs alone,
using conventional vaccination strategies, are unsuitable for
inducing immunoprotection against Leishmania infections;
however, these studies do not preclude their use as either
immunomodulators or, alternatively, vaccine candidates if
diﬀerent vaccination approaches are followed.
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